Here Are the New Drugs and Treatments We Could See in 2024
2023 was a strong year for innovative new drugs, but 2024 is also shaping up to be a milestone year for some exciting therapies.
Eli Lilly could debut a new treatment for Alzheimer's disease that targets amyloid, the protein that builds up in the brains of patients.
Revolutionary gene therapy may offer new life for patients battling chronic sickle cell disease
Gene therapy using CRISPR/Cas9 has been approved by federal regulators as a potential treatment for sickle cell disease.
The University of Chicago Medicine and the University of Illinois at Chicago are among the first medical centers to offer this groundbreaking therapy.
People with Sickle Cell Deserve More Respect from Health Care Providers
The recent approval of gene-editing treatments for sickle cell disease provides hope for relief from pain and reduced lifespan.
Access to these high-tech treatments remains uncertain and marginalized communities must continue to be supported in their healthcare.
'It's Transformed My Life': FDA Approves First Gene-Editing Treatment for Illness | KQED
The CRISPR treatment for sickle cell disease involves editing a gene with CRISPR and infusing the modified cells back into patients.
The therapy, Casgevy, is designed to be a one-time treatment that alleviates symptoms for a lifetime.
FDA Approves First CRISPR Treatment in U.S.
The U.S. FDA has approved the first gene therapy treatment based on CRISPR technology.
The treatment, called exa-cel, is approved for sickle cell disease and may also be approved for beta thalassemia.
FDA approves first CRISPR gene editing treatment that may cure sickle cell disease
Regulators have approved two new gene therapies for sickle cell disease that could potentially cure the inherited blood disorder.
The treatments are the first to be approved based on CRISPR, the gene editing tool that won its inventors the Nobel Prize in 2020.
Breakthrough Gene Treatments For Sickle Cell Disease Approved
Regulators have approved two new gene therapies for sickle cell disease, offering hope for a cure for the painful blood disorder
The treatments are designed for patients 12 and older with severe forms of the disease, and one of them is the first therapy based on CRISPR gene editing
The CRISPR Era Is Here
Gene-editing technology CRISPR has successfully treated a patient with sickle-cell disease, providing hope for future treatments.
The treatment resulted in the patient living virtually symptom-free, with 29 out of 30 eligible patients experiencing zero pain crises after treatment.